Galcanezumab in chronic migraine
The randomized, double-blind, placebo-controlled REGAIN study

Holland C. Detke, PhD, Peter J. Goadsby, MD, PhD, Shufang Wang, PhD, Deborah I. Friedman, MD, MPH, Katherine J. Selzler, PhD, and Sheena K. Aurora, MD

Neurology® 2018;91:e2211-e2221. doi:10.1212/WNL.0000000000006640

Correspondence
Dr. Detke
detkehc@lilly.com

Abstract

Objective
To evaluate the efficacy and safety of galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, in the preventive treatment of chronic migraine.

Methods
A phase 3, randomized, double-blind, placebo-controlled study of LY2951742 in patients with chronic migraine (Evaluation of Galcanezumab in the Prevention of Chronic Migraine [REGAIN]) was a phase 3 study with a 3-month double-blind, placebo-controlled treatment phase and a 9-month open-label extension. Eligible patients 18 to 65 years of age with chronic migraine were randomized 2:1:1 to monthly subcutaneous injections of placebo (n = 558), galcanezumab 120 mg (with a 240-mg loading dose, n = 278), or galcanezumab 240 mg (n = 277). The primary endpoint was the overall mean change from baseline in the number of monthly migraine headache days (MHDs) during the 3-month double-blind treatment phase.

Results
Mean number of monthly MHDs at baseline was 19.4 for the total sample. Both galcanezumab dose groups demonstrated greater overall mean reduction in the number of monthly MHDs compared to placebo (placebo −2.7, galcanezumab 120 mg −4.8, galcanezumab 240 mg −4.6) (p < 0.001 for each dose compared to placebo). There were no clinically meaningful differences between galcanezumab doses and placebo on any safety or tolerability outcome except for a higher incidence of treatment-emergent injection-site reaction (p < 0.01), injection-site erythema (p < 0.001), injection-site pruritus (p < 0.01), and sinusitis (p < 0.05) in the galcanezumab 240-mg group relative to placebo.

Conclusions
Both doses of galcanezumab were superior to placebo in reducing the number of monthly MHDs. Galcanezumab appears efficacious, safe, and well tolerated for the preventive treatment of chronic migraine.

ClinicalTrials.gov identifier
NCT02614261.

Classification of evidence
This interventional study provides Class I evidence that galcanezumab is superior to placebo in the reduction of the number of monthly MHDs.
Chronic migraine (CM) is a neurologic disease characterized by at least 15 headache days per month, of which at least 8 are migraine.\(^1\) Although less prevalent than episodic migraine, CM is associated with substantially greater headache-related disability, comorbid medical and psychiatric conditions, and health care resource use and poorer quality of life.\(^2\) Individuals with CM are at particularly high risk for headache associated with acute medication overuse, which may exacerbate the disease.\(^3\) Therefore, it is of critical importance to develop effective and well-tolerated migraine preventive treatments to reduce disability and to prevent disease progression.

Calcitonin gene-related peptide (CGRP) is a promising target for migraine prevention.\(^4\) Three previous monoclonal antibodies to CGRP or one of its receptors have been studied as preventive therapy for CM. Eptinezumab,\(^5\) fremanezumab,\(^6\) and erenumab\(^7\) have shown efficacy in either phase 2 or phase 3 clinical trials in patients with CM. Galcanezumab is a humanized monoclonal antibody that selectively binds to and blocks the physiologic activity of CGRP.\(^8\) Patients with episodic migraine treated with galcanezumab had a significantly greater mean reduction in the number of monthly migraine headache days (MHDs) and low rates of treatment discontinuation compared with those treated with placebo.\(^9\)–\(^12\) The present report includes results from the 3-month double-blind period of a phase 3 clinical trial of galcanezumab in patients with CM. to determine patient eligibility on the basis of daily entries into an electronic patient-reported outcomes (ePRO) diary; (3) a 3-month randomized, double-blind, placebo-controlled treatment period; (4) a 9-month open-label extension; and (5) a 4-month posttreatment period to observe the washout of the study drug. Here, we report results through the double-blind treatment period (study period 3). Results from the open-label and posttreatment periods will be reported separately.

Patient selection
Patients were men and women 18 to 65 years of age at screening with a diagnosis of CM as defined by the International Classification of Headache Disorders, 3rd edition, beta version (ICHD-3 beta) guidelines\(^1\) and migraine onset before 50 years of age. Patients had to have at least 15 headache days per month, of which at least 8 were migraine, for \(>3\) months before screening and as assessed by the ePRO diary during the 1-month prospective baseline period. Patients also needed at least 1 headache-free day per month within 3 months before screening and during baseline. Patients had to be at least 80% compliant with ePRO daily diary entries and were blinded to diary eligibility criteria.

We excluded patients who had persistent daily headache, cluster headache, head or neck trauma within the past 6 months, possible posttraumatic headache, or primary headache other than CM. Patients could not have previously failed to respond to adequate trials of migraine preventives with Level A or Level B evidence from \(>3\) different medication classes (based on the list of such preventives found in the American Academy of Neurology’s evidence-based guidelines\(^13\) or onabotulinumtoxinA or B). Patients could not take therapeutic antibodies during or within 1 year before the study and could not have serious or unstable medical or psychiatric conditions, history of stroke, or history of substance abuse or dependence in the past year or be at risk for acute cardiovascular events based on history or ECG findings.

Patients could take acute headache medication as needed throughout the trial but could take opioid- or barbiturate-containing medications no more than 3 days per month, could not take oral corticosteroids, and could receive no more than 1 steroid injection during the study and only if in an emergency setting. Patients had to wash out all migraine preventive medications except topiramate or propranolol; patients could remain on either topiramate or propranolol if on a stable dose in the 2 months before starting the prospective baseline period and remaining on that dose throughout the baseline and double-blind periods. Patients staying on topiramate or

---

**Glossary**

ADA = anti-drug antibodies; AE = adverse event; CM = chronic migraine; CGRP = calcitonin gene-related peptide; ePRO = electronic patient-reported outcomes; ICHD = International Classification of Headache Disorders, 3rd edition, beta version; MHD = migraine headache day; MIDAS = Migraine Disability Assessment; MSQ = Migraine-Specific Quality of Life Questionnaire; PGI-S = Patient Global Impression of Severity of Illness; REGAIN = Evaluation of Galcanezumab in the Prevention of Chronic Migraine.

Chronic migraine (CM) is a neurologic disease characterized by at least 15 headache days per month, of which at least 8 are migraine.\(^1\) Although less prevalent than episodic migraine, CM is associated with substantially greater headache-related disability, comorbid medical and psychiatric conditions, and health care resource use and poorer quality of life.\(^2\) Individuals with CM are at particularly high risk for headache associated with acute medication overuse, which may exacerbate the disease.\(^3\) Therefore, it is of critical importance to develop effective and well-tolerated migraine preventive treatments to reduce disability and to prevent disease progression.

Calcitonin gene-related peptide (CGRP) is a promising target for migraine prevention.\(^4\) Three previous monoclonal antibodies to CGRP or one of its receptors have been studied as preventive therapy for CM. Eptinezumab,\(^5\) fremanezumab,\(^6\) and erenumab\(^7\) have shown efficacy in either phase 2 or phase 3 clinical trials in patients with CM. Galcanezumab is a humanized monoclonal antibody that selectively binds to and blocks the physiologic activity of CGRP.\(^8\) Patients with episodic migraine treated with galcanezumab had a significantly greater mean reduction in the number of monthly migraine headache days (MHDs) and low rates of treatment discontinuation compared with those treated with placebo.\(^9\)–\(^12\) The present report includes results from the 3-month double-blind period of a phase 3 clinical trial of galcanezumab in patients with CM.
propranolol were known as the concurrent migraine preventive cohort. Otherwise, patients discontinued all migraine preventives at least 30 days before entering the baseline period (or at least 4 months prior for botulinum toxin).

**Randomization and masking**

Eligible patients were randomized 2:1:1 to receive monthly subcutaneous injections of placebo, galcanezumab 120 mg (with a 240-mg loading dose), or galcanezumab 240 mg for the 3-month double-blind period. Assignment to treatment was via computer-generated random sequence with an interactive web-response system. Randomization was stratified by country, acute headache medication overuse (yes/no) as determined during prospective baseline, and presence of concurrent migraine preventive (yes/no).

To preserve blinding, patients in all treatment groups received two 1-mL injections at each monthly dosing visit (2 placebo injections, 1 placebo and 1 galcanezumab 120-mg injection, or 2 galcanezumab 120-mg injections) in blinded prefilled syringes. Patients in the galcanezumab 120-mg group received 240 mg at their first dosing visit, followed by 120 mg at the subsequent months. All patients had to remain in the office for a 30-minute postinjection observation period after the first dose.

**Study objectives and measures**

The primary objective tested the hypothesis that at least 1 dose of galcanezumab (120 or 240 mg/mo) was superior to placebo in the prevention of migraine in patients with CM as measured by the overall mean change from baseline in the number of monthly MHDs during the 3-month double-blind treatment period. An MHD was a calendar day with a headache lasting ≥30 minutes, with features meeting ICHD-3 beta criteria for migraine or probable migraine. A headache also qualified as a migraine if the patient believed it was a migraine at onset and was relieved by a triptan or ergot. A headache day was a calendar day with any headache lasting ≥30 minutes (including migraine, probable migraine, and nonmigraine headache).

Key secondary objectives compared galcanezumab with placebo on response rates (proportion of patients with ≥50%, ≥75%, and 100% reduction from baseline in monthly MHDs across months 1–3), mean change in functioning at month 3 measured by the Migraine-Specific Quality of Life Questionnaire (MSQ) Role Function-Restrictive score, overall mean reduction in monthly MHDs with acute headache medication use across months 1 to 3, and mean change in Patient Global Impression of Severity of Illness (PGI-S) at month 3. Other secondary objectives included comparison of galcanezumab with placebo on additional headache parameters (e.g., monthly headache days, headache hours, and migraine headache hours) across months 1 to 3, and the Migraine Disability Assessment (MIDAS) total score at month 3.

Patients reported all headache information in the ePRO diary, including duration, severity, and features, as well as drug name and dose of acute headache medications taken that calendar day. Patients completed self-report scales at office visits, including the MSQ (monthly), PGI-S (monthly), and MIDAS (every 3 months). The MSQ version 2.1 assesses the effect of migraine on daily functioning in 3 domains over a 4-week recall period: Role Function-Restrictive (7 items), Role Function-Preventive (4 items), and Emotional Function (3 items). The MSQ items are rated on a scale of 1 to 6, with domain scores converted to a scale of 0 to 100 such that higher scores represent better functioning. The PGI-S scale is a single-item instrument asking patients to rate the severity of their overall migraine illness on a scale of 1 (normal, not at all ill) to 7 (extremely ill). The MIDAS is a 5-item patient-rated instrument assessing number of days negatively affected by migraine during the 3-month recall period, with scores ≥21 representing severe disability.

Double-blind safety assessments included adverse events (AEs) (all visits), vital signs (monthly), and weight, laboratory measures, ECGs (baseline and month 3), and treatment-emergent anti-drug antibodies (ADA; all visits). Suicidality was assessed monthly by the Columbia-Suicide Severity Scale, a required assessment for all investigational neurologic treatments.

**Statistical analysis**

The target sample size was 1,140, based on the assumption of a 15% discontinuation rate and an effect size of 0.30 in the last month of the 3-month treatment phase, to provide ≈95% power that at least 1 galcanezumab group would separate from placebo at a 1-sided 0.025 significance level.

We conducted analyses on all randomized patients receiving at least 1 dose of study medication. We conducted efficacy analyses on an intent-to-treat basis, with patients analyzed according to assigned treatment group. We conducted safety analyses according to patients’ modal dose rather than the assigned dose. Five patients assigned to 120-mg galcanezumab had a modal dose of 240 mg because they discontinued after the loading dose and before the first maintenance dose.

We performed analyses of continuous repeated efficacy measures using a restricted maximum likelihood-based mixed-models repeated-measures technique with prespecified model terms of treatment, country, acute headache medication overuse, concurrent preventive use, month, treatment × month, baseline × month. Overall mean change from baseline (i.e., the average change across months 1–3) is estimated from the model. For continuous safety and efficacy analyses with objectives evaluated at month 3 (PGI-S and MIDAS), we used an analysis of covariance model to analyze change from baseline to last-observation-carried-forward endpoint. Response rates represent the mean percentage of responders from the categorical, pseudo–likelihood-based repeated-measures analysis assessing overall response rate across months 1, 2, and 3. We used the Fisher exact test to...
analyze demographic and baseline illness characteristics. For
categorical safety analyses, we used the Cochran-Mantel-
Haenszel test for between-group comparisons, adjusting for
baseline medication overuse and concurrent preventive
medication use.

We adjusted for multiplicity in the primary and prespecified
key secondary analyses using a superchain procedure to
test for type I error. Hypothesis testing occurred se-
quentially through parallel dose branches, with the possibility
to recycle available α as depicted in figure 1, which includes
notational conventions consistent with that of previously
described methods. We calculated multiplicity-adjusted a
thresholds for each hypothesis in each step of the pro-
cedure using the appropriate multiplicity adjustment
technique (the Dunnett test, the Hochberg procedure,
or the Bonferroni-Holm procedure). We then compared
the unadjusted p value for each hypothesis against its
multiplicity-adjusted a level. We considered endpoints with
an unadjusted p value higher than the adjusted a level to be
not statistically significant after multiplicity adjustment.

Once we failed to reject the null hypothesis for an endpoint
in the sequence (including any retesting with any available
recycled a), we stopped the procedure and did not test any
further endpoints in the sequence for that dose branch. We
automatically considered any untested endpoints in the
sequence as not statistically significant after multiplicity
adjustment.

We performed all statistical analyses using SAS Enterprise

**Figure 1 Multiple testing procedure**

![Diagram](Image)

Arrows indicate direction and weighting of a
propagation. The procedure initially tests
the parallel branches (dose sequences) si-
multaneously and then recycles available α
between the branches to retest endpoint
families containing nonrejected null hypoth-
eses. Notation is consistent with previously
reported methods. Acute meds = MHD
with the use of acute (abortive) treatment;
MHD = migraine headache days (mean
change from baseline); MSQ = Migraine-Spe-
cific Quality of Life Questionnaire Role Func-
tion-Restrictive domain; PGI-S = Patient Global
Impression of Severity; RR = response rate.

**Data availability**

Lilly makes patient-level data available from Lilly-sponsored
studies on marketed drugs for approved uses after acceptance
for publication. Lilly is one of several companies that provide
this access through the website clinicalstudydatarequest.com.
Qualified researchers can submit research proposals and re-
quest anonymized data to test new hypotheses. Lilly’s data-
sharing policies are provided on the clinicalstudydatarequest.
com site under the Study Sponsors page.

**Classification of evidence**

This interventional study provides Class I evidence for the
primary research question, namely that both dose regimens of
galcanezumab (120 mg/mo with a 240-mg loading dose and
240 mg/mo) are superior to placebo in the reduction of the
number of monthly MHDs.

**Results**

**Patient disposition**

Of 1,903 patients screened, we randomized 1,117 (figure 2).
Four did not receive the study drug, leaving 1,113 in the
intent-to-treat population. More than 90% of the patients in
each treatment group completed the double-blind treatment
period (figure 2).

**Patient demographics and baseline characteristics**

Demographic and baseline characteristics were generally
similar across treatment groups (table 1). The galcanezumab
240-mg group had a higher percentage of patients who had
prior treatment failure of ≥2 migraine preventives in the past 5 years (35%) compared with the galcanezumab 120-mg group (24%). There were also a few statistical differences from placebo in the galcanezumab 240-mg group, but they were not clinically meaningful. Only 15% of patients overall remained on a concurrent preventive (topiramate or propranolol) during the study.

Efficacy outcomes
On the primary endpoint, both doses of galcanezumab were superior to placebo in the overall mean reduction in the number of monthly MHDs from baseline (table 2). Monthly reductions in MHDs were statistically different from placebo for both galcanezumab doses starting with month 1 (figure 3). Over the 3 months of treatment, the mean percentages of patients with ≥50% and ≥75% reduction from baseline in MHDs were higher for both galcanezumab doses than for placebo (≥50% response rate: both doses p < 0.001; ≥75% response rate: 120 mg p < 0.05, 240 mg p < 0.001; figure 4). After adjustment for multiplicity, galcanezumab 240 mg demonstrated statistical improvement vs placebo on the primary and all key secondary endpoints except for 100% response rate, while galcanezumab 120 mg had statistical improvement vs placebo on the primary endpoint and the ≥50% response rate (table 2). Results for other (nonkey) secondary measures are presented in table 2. There were no statistical differences between doses on any efficacy measure.

Safety
There were no deaths in this study. Treatment-emergent AEs were reported by 50%, 58%, and 57% of patients in the placebo, galcanezumab 120-mg, and galcanezumab 240-mg groups, respectively (table 3). Most treatment-emergent AEs were mild or moderate in severity. The most common treatment-emergent AE was injection-site pain, but this did not differ significantly between groups (4% placebo, 6% galcanezumab 120 mg, 7% galcanezumab 240 mg). Injection-site reaction, injection-site erythema, injection-site pruritus, and sinusitis occurred more frequently in the galcanezumab 240-mg group relative to placebo, with injection-site pruritus and injection-site erythema also occurring more frequently with the 240-mg than the 120-mg galcanezumab dose. Six placebo-treated patients discontinued as a result of AEs that included abdominal pain, alopecia, headache, migraine, and myocardial infarction. Five galcanezumab-treated patients discontinued because of an AE that included increased weight in the 120-mg group and depression, increased hepatic enzymes, injection-site pain, and acute pancreatitis in the 240-mg group.

There were 10 serious AEs during the study, with 4 reported in the placebo group (alcoholic pancreatitis, epistaxis, gastritis, and myocardial infarction), 1 in the galcanezumab 120-mg group (colon cancer), and 5 in the galcanezumab 240-mg group (hypokalemia and nephrolithiasis in 1 patient, acute pancreatitis, pulmonary embolism, and renal colic).

We observed no clinically meaningful differences between galcanezumab and placebo in laboratory values, vital signs, weight, or quantitative or qualitative ECGs. Two patients in the study had a treatment-emergent abnormal hepatic enzyme: 1 in the placebo group (1 of 558 or 0.2%) and 1 in the galcanezumab 240-mg dose group (1 of 282 or 0.4%).

Treatment-emergent suicidal ideation assessed by the Columbia-Suicide Severity Scale was reported for 4 (1%) patients on placebo, 3 (1%) patients in the galcanezumab 120-mg group, and 2 (1%) patients in the galcanezumab 240-mg group, with no suicidal behavior.

**Anti-drug antibodies**

During the double-blind treatment phase, treatment-emergent ADA occurred in 22 patients across the groups (1.5%, 2.7%, and 2.6% of the placebo, galcanezumab 120-mg, and galcanezumab 240-mg groups, respectively). Of these 22 patients, 13 had neutralizing ADA present (0.6%, 2.3%, and 1.5% of the placebo, galcanezumab 120-mg, and galcanezumab 240-mg groups, respectively).

---

**Table 1** Patient demographics and baseline disease characteristics

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n = 558)</th>
<th>Galcanezumab 120 mg (n = 278)</th>
<th>Galcanezumab 240 mg (n = 277)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, y</strong></td>
<td>41.6 (12.1)</td>
<td>39.7 (11.9)*</td>
<td>41.1 (12.4)</td>
</tr>
<tr>
<td><strong>Female, n (%)</strong></td>
<td>483 (87)</td>
<td>237 (85)</td>
<td>226 (82)</td>
</tr>
<tr>
<td><strong>Race, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>432 (77)</td>
<td>223 (80)</td>
<td>224 (81)</td>
</tr>
<tr>
<td>Black</td>
<td>39 (7)</td>
<td>16 (6)</td>
<td>17 (6)</td>
</tr>
<tr>
<td>Asian</td>
<td>26 (5)</td>
<td>13 (5)</td>
<td>14 (5)</td>
</tr>
<tr>
<td>Other</td>
<td>61 (11)</td>
<td>26 (9)</td>
<td>21 (8)</td>
</tr>
<tr>
<td><strong>Body mass index, kg/m²</strong></td>
<td>26.9 (5.6)</td>
<td>26.4 (5.5)</td>
<td>26.7 (5.2)</td>
</tr>
<tr>
<td><strong>Migraine illness duration, y</strong></td>
<td>21.9 (12.9)</td>
<td>20.4 (12.7)</td>
<td>20.1 (12.7)*</td>
</tr>
<tr>
<td><strong>MHD/mo</strong></td>
<td>19.6 (4.6)</td>
<td>19.4 (4.3)</td>
<td>19.2 (4.6)</td>
</tr>
<tr>
<td><strong>MHD/mo with acute medication use</strong></td>
<td>15.5 (6.6)</td>
<td>15.1 (6.3)</td>
<td>14.5 (6.3)*</td>
</tr>
<tr>
<td><strong>Headache d/mo</strong></td>
<td>21.5 (4.1)</td>
<td>21.2 (4.0)</td>
<td>21.4 (4.1)</td>
</tr>
<tr>
<td><strong>Migraine headache h/mo</strong></td>
<td>136.7 (91.0)</td>
<td>136.0 (79.5)</td>
<td>134.7 (86.6)</td>
</tr>
<tr>
<td><strong>Headache h/mo</strong></td>
<td>145.1 (95.1)</td>
<td>144.7 (85.4)</td>
<td>145.9 (93.4)</td>
</tr>
<tr>
<td><strong>Patient-reported aura, n (%)</strong></td>
<td>310 (56)</td>
<td>153 (55)</td>
<td>141 (51)</td>
</tr>
<tr>
<td><strong>Prior preventive treatment in past 5 y, n (%)</strong></td>
<td>435 (78)</td>
<td>211 (76)</td>
<td>220 (79)</td>
</tr>
<tr>
<td><strong>Failed ≥2 preventives in past 5 y, n (%)</strong></td>
<td>163 (29)</td>
<td>68 (24)</td>
<td>97 (35)*</td>
</tr>
<tr>
<td><strong>Acute headache medication overuse, n (%)</strong></td>
<td>353 (63)</td>
<td>178 (64)</td>
<td>177 (64)</td>
</tr>
<tr>
<td><strong>Concurrent preventive treatment, n (%)</strong></td>
<td>82 (15)</td>
<td>37 (13)</td>
<td>43 (16)</td>
</tr>
<tr>
<td><strong>MIDAS total score</strong></td>
<td>68.7 (57.4)</td>
<td>62.5 (49.5)</td>
<td>69.2 (64.1)</td>
</tr>
<tr>
<td><strong>MSQ RF-R score</strong></td>
<td>38.4 (17.2)</td>
<td>39.3 (17.3)</td>
<td>38.9 (17.3)</td>
</tr>
<tr>
<td><strong>MSQ RF-P score</strong></td>
<td>55.0 (20.8)</td>
<td>55.5 (22.0)</td>
<td>57.1 (20.5)</td>
</tr>
<tr>
<td><strong>MSQ EF score</strong></td>
<td>44.2 (26.0)</td>
<td>45.3 (25.8)</td>
<td>45.7 (27.4)</td>
</tr>
<tr>
<td><strong>PGI-S score</strong></td>
<td>4.9 (1.2)</td>
<td>4.8 (1.2)</td>
<td>4.9 (1.3)</td>
</tr>
</tbody>
</table>

Abbreviations: EF = Emotional Function; MHD = migraine headache days; MIDAS = Migraine Disability Assessment; MSQ = Migraine-Specific Quality of Life Questionnaire version 2.1; PGI-S = Patient Global Impression-Severity of Illness; RF-P = Role Function-Preventive; RF-R = Role Function-Restrictive.

Data are mean (SD) unless otherwise indicated.

* p ≤ 0.05 vs placebo.

† p ≤ 0.01 vs galcanezumab 120 mg.
Table 2 Primary and secondary endpoints (time frame is across months 1 through 3 unless otherwise specified)

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n = 538)</th>
<th>Galcanezumab 120 mg (n = 273)</th>
<th>Galcanezumab 240 mg (n = 274)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary endpoint</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monthly MHDs</td>
<td>–2.7 (0.4)</td>
<td>–4.8 (0.4)</td>
<td>–4.6 (0.4)</td>
</tr>
<tr>
<td>Difference (95% CI)</td>
<td>–2.1 (–2.9 to –1.3)</td>
<td>–1.9 (–2.7 to –1.1)</td>
<td></td>
</tr>
<tr>
<td>p Value vs placebo*</td>
<td>&lt;0.001 (S)</td>
<td>&lt;0.001 (S)</td>
<td></td>
</tr>
<tr>
<td><strong>Key secondary endpoints</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥50% response</td>
<td>15.4 (1.6)</td>
<td>27.6 (2.7)</td>
<td>27.5 (2.6)</td>
</tr>
<tr>
<td>Odds ratio (95% CI)</td>
<td>2.1 (1.6 to 2.8)</td>
<td>2.1 (1.6 to 2.8)</td>
<td></td>
</tr>
<tr>
<td>p Value vs placebo*</td>
<td>&lt;0.001 (S)</td>
<td>&lt;0.001 (S)</td>
<td></td>
</tr>
<tr>
<td>≥75% response</td>
<td>4.5 (0.9)</td>
<td>7.0 (1.4)</td>
<td>8.8 (1.7)</td>
</tr>
<tr>
<td>Odds ratio (95% CI)</td>
<td>1.6 (1.0 to 2.5)</td>
<td>2.0 (1.4 to 3.1)</td>
<td></td>
</tr>
<tr>
<td>p Value vs placebo*</td>
<td>0.031 (NS)</td>
<td>&lt;0.001 (S)</td>
<td></td>
</tr>
<tr>
<td>100% response</td>
<td>0.5 (0.3)</td>
<td>0.7 (0.4)</td>
<td>1.3 (0.6)</td>
</tr>
<tr>
<td>Odds ratio (95% CI)</td>
<td>1.4 (0.4 to 4.4)</td>
<td>2.6 (1.0 to 7.0)</td>
<td></td>
</tr>
<tr>
<td>p Value vs placebo*</td>
<td>0.597 (NS)b</td>
<td>0.058 (NS)</td>
<td></td>
</tr>
<tr>
<td>Monthly MHDs with acute medication use</td>
<td>–2.2 (0.3)</td>
<td>–4.7 (0.4)</td>
<td>–4.3 (0.4)</td>
</tr>
<tr>
<td>Difference (95% CI)</td>
<td>–2.5 (–3.3 to –1.8)</td>
<td>–2.0 (–2.8 to –1.3)</td>
<td></td>
</tr>
<tr>
<td>p Value vs placebo*</td>
<td>&lt;0.001 (NS)b</td>
<td>&lt;0.001 (S)</td>
<td></td>
</tr>
<tr>
<td>MSQ RF-R scorec</td>
<td>16.8 (1.2)</td>
<td>21.8 (1.4)</td>
<td>23.1 (1.6)</td>
</tr>
<tr>
<td>Difference (95% CI)</td>
<td>5.1 (2.1 to 8.0)</td>
<td>6.3 (3.0 to 9.6)</td>
<td></td>
</tr>
<tr>
<td>p Value vs placebo*</td>
<td>&lt;0.001 (NS)b</td>
<td>&lt;0.001 (S)</td>
<td></td>
</tr>
<tr>
<td>PGI-S scorec</td>
<td>–0.6 (0.1)</td>
<td>–0.8 (0.1)</td>
<td>–0.9 (0.1)</td>
</tr>
<tr>
<td>Difference (95% CI)</td>
<td>–0.1 (–0.3 to 0.1)</td>
<td>–0.3 (–0.5 to –0.1)</td>
<td></td>
</tr>
<tr>
<td>p Value vs placebo*</td>
<td>0.181 (NS)b</td>
<td>0.006 (S)</td>
<td></td>
</tr>
<tr>
<td><strong>Other secondary endpoints</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monthly headache days</td>
<td>–3.0 (0.4)</td>
<td>–4.8 (0.4)</td>
<td>–4.6 (0.4)</td>
</tr>
<tr>
<td>Difference (95% CI)</td>
<td>–1.8 (–2.7 to –1.0)</td>
<td>–1.6 (–2.4 to –0.8)</td>
<td></td>
</tr>
<tr>
<td>p Value vs placebo*</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Monthly headache hours</td>
<td>–13.4 (3.9)</td>
<td>–36.2 (4.7)</td>
<td>–31.5 (4.7)</td>
</tr>
<tr>
<td>Difference (95% CI)</td>
<td>–22.7 (–31.7 to –13.7)</td>
<td>–18.1 (–27.1 to –9.1)</td>
<td></td>
</tr>
<tr>
<td>p Value vs placebo*</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Monthly migraine headache hours</td>
<td>–14.1 (3.8)</td>
<td>–36.2 (4.6)</td>
<td>–32.1 (4.6)</td>
</tr>
<tr>
<td>Difference (95% CI)</td>
<td>–22.1 (–30.9 to –13.3)</td>
<td>–18.0 (–26.8 to –9.3)</td>
<td></td>
</tr>
<tr>
<td>p Value vs placebo*</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>MSQ RF-P scorec</td>
<td>11.0 (1.2)</td>
<td>18.0 (1.4)</td>
<td>16.1 (1.4)</td>
</tr>
<tr>
<td>Difference (95% CI)</td>
<td>7.0 (4.2 to 9.8)</td>
<td>5.1 (2.3 to 7.9)</td>
<td></td>
</tr>
<tr>
<td>p Value vs placebo*</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

Continued
240-mg groups, respectively), with a statistical difference between galcanezumab 120 mg and placebo ($p < 0.05$). Maximum ADA titers among these patients ranged from 1:20 to 1:160. There was no discernible effect of ADA on treatment efficacy or tolerability.

**Discussion**

This 3-month phase 3 study met its primary objective in that both doses of galcanezumab were superior to placebo in the overall mean reduction of monthly MHDs in CM. There was no previous phase 2 study of galcanezumab in patients with CM. Patients in this study had an average of 19.3 MHDs per month and an average MIDAS score of 65.8, indicating very severe $^{27}$ disability. Monthly MHDs decreased by $\approx 5$, with a difference from placebo of 2 MHDs, representing a clinically meaningful, positive change. $^{28}$ Despite the high MHD frequency and relatively short duration of the study, the percentage of patients with $\geq 50\%$ reduction in the number of monthly MHDs was $>25\%$ in both galcanezumab dose groups, and almost twice as many galcanezumab-treated patients had $\geq 75\%$ reduction compared with placebo. The mean increase in functioning by 23 points on the 100-point MSQ Role Function-Restrictive domain for the galcanezumab 240-mg group also represents a clinically important change; these patients with CM improved to a level of functioning more consistent with that of episodic migraine. Efficacy results appeared generally consistent with those from other

**Table 2** Primary and secondary endpoints (time frame is across months 1 through 3 unless otherwise specified) *(continued)*

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n = 538)</th>
<th>Galcanezumab 120 mg (n = 273)</th>
<th>Galcanezumab 240 mg (n = 274)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MSQ EF score</strong></td>
<td>14.1 (1.6)</td>
<td>21.0 (1.9)</td>
<td>20.7 (1.9)</td>
</tr>
<tr>
<td>Difference (95% CI)</td>
<td></td>
<td>7.0 (3.2 to 10.8)</td>
<td>6.6 (2.8 to 10.4)</td>
</tr>
<tr>
<td>$p$ Value vs placebo</td>
<td>$&lt;0.001$</td>
<td>$&lt;0.001$</td>
<td></td>
</tr>
<tr>
<td><strong>MIDAS total score</strong></td>
<td>$-11.5 (3.4)$</td>
<td>$-20.3 (4.1)$</td>
<td>$-17.0 (4.1)$</td>
</tr>
<tr>
<td>Difference (95% CI)</td>
<td></td>
<td>$-8.7 (-16.4 to -1.1)$</td>
<td>$-5.5 (-13.1 to 2.1)$</td>
</tr>
<tr>
<td>$p$ Value vs placebo</td>
<td>$0.025$</td>
<td>$0.157$</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CI = confidence interval; EF = Emotional Function; MHD = migraine headache day; MIDAS = Migraine Disability Assessment; MSQ = Migraine-Specific Quality of Life version 2.1; NS = not significant after multiplicity adjustment; RF-P = Role Function-Preventive; RF-R = Role Function-Restrictive; PGI-S = Patient Global Impression of Severity of Illness; S = significant after multiplicity adjustment.

Data are least-squares mean change from baseline (SE) or estimated percentage (SE) unless otherwise stated.

a $p$ Value indicates nominal significance without multiplicity adjustment; S or NS indicates significant or not significant after multiplicity adjustment.

b Item not tested after all $\alpha$ expended on previous items in multiplicity adjustment testing sequence (figure 1). Therefore, item is considered not statistically significant regardless of $p$ value.

c Time frame is at month 3.
large randomized double-blind trials evaluating a preventive treatment in a CM population such as those for CGRP pathway blockers, onabotulinumtoxinA, and topiramate. In addition to efficacy, the safety and tolerability profiles are essential components in evaluating the overall therapeutic benefit of a treatment investigated in a clinical trial. The high rates of study completion (95%) and low rates of discontinuation due to AEs (1%) for the galcanezumab-treated patients suggest that galcanezumab was well tolerated, consistent with findings in the episodic migraine studies. Incidences of individual treatment-emergent AEs were low, with the most common being injection-site pain (6%–7% across galcanezumab doses). Incidences of injection-site related treatment-emergent AEs such as injection-site reaction, injection-site erythema, and injection-site pruritus were also low but reported in a greater proportion of patients receiving galcanezumab 240 mg compared with placebo. Most injection-site reactions were mild to moderate in severity and resolved within a few days, with no serious events. In addition, there were no clinically meaningful differences from placebo with respect to changes in laboratory parameters, vital signs, or ECGs.

Comparison of the 2 galcanezumab doses yielded few differences. Although the galcanezumab 240-mg dose met statistical significance on more key secondary endpoints after multiplicity adjustment than did the 120-mg dose, there were no statistical differences between the 2 doses on any of the efficacy measures. Together, the data suggest that the galcanezumab 120-mg dose performed as well as the galcanezumab 240-mg dose with respect to reductions in monthly MHDs, other migraine and headache parameters, and improvements in functioning and quality of life. With respect to safety and tolerability, the incidences of injection-site erythema and injection-site pruritus were higher in the galcanezumab 240-mg group than the 120-mg group. Otherwise, the 2 doses appeared quite similar. Some limitations should be noted. Restrictions in the inclusion criteria may limit the generalizability of the results. Patients with serious and unstable medical conditions were excluded, as were patients who had demonstrated significant treatment-resistance to multiple previous migraine preventive medications. In addition, the 3-month duration of the study, while sufficient to demonstrate efficacy, may not be long enough to demonstrate the ultimate effects of the treatment; here, analysis of the 9-month open-label extension may help. Nevertheless, further study is needed to evaluate both the benefits and risks of long-term use of galcanezumab in the CM patient population.

This phase 3 trial of galcanezumab for prevention of CM demonstrated that both doses of galcanezumab were efficacious, safe, and well tolerated after treatment for up to 3 months. These findings contribute further support that the CGRP pathway inhibition is a biologically specific, disease-targeted approach to the prevention of migraine that offers an important advance in the management of a common and disabling neurologic disease.

**Author contributions**

Dr. Detke contributed to the study design, interpretation of data, and creating/revising the content. Dr. Goadsby contributed to the interpretation of data and revised the manuscript for content. Dr. Wang contributed to the analyses of data and study design and revised the manuscript for content. Dr. Friedman, Dr. Selzler, and Dr. Aurora revised the manuscript for content.
Acknowledgment
The authors thank all of the study participants, site investigators, and personnel involved in the Evaluation of Galcanezumab in the Prevention of Chronic Migraine (REGAIN) study. They also thank Vladimir Skljarevski, MD, Brian Millen, PhD, and Jyun Yan Yang, MD, for their contributions during the study and Jonna Ahl, PhD, for assistance in drafting the manuscript.

Study funding
Study was funded by Eli Lilly and Company. This work has been reported previously at the American Headache Society and International Headache Society meetings in 2017.

Disclosure
H. Detke is a full-time employee and minor shareholder of Eli Lilly and Company. P. Goadsby reports grants from Eli Lilly and Company; personal fees from Alder BioPharmaceuticals, Dr Reddy’s Laboratories, Electrocore LLC, Novartis, Pfizer Inc, Scion, Teva Pharmaceuticals, medicolegal work, Journal Watch, Up-to-Date, Oxford University Press, Massachusetts Medical Society, and Wolters Kluwer; and grants and personal fees from Allergan, Amgen, and eNeura Inc; and other from Trigemina Inc. In addition, Dr. Goadsby has a patent for magnetic stimulation for headache licensed to eNeura without fee. S. Wang is a full-time employee and minor shareholder of Eli Lilly and Company. D. Friedman reports speaker fees from Allergan; advisory board and speaker fees from Supernus and Amgen; advisory board, consultant, and speaker fees from Avanir; advisory board fees from Alder BioPharmaceuticals and Biohaven Pharmaceuticals; consultant and advisory board fees from electroCore; advisory board and grant support from Teva and Zosano; grant support and consultant fees from Eli Lilly and Company; and grant support from Merck, Autonomic Technologies, Inc, and Axon Optics. D. Friedman has been a consultant for Promius, serves on editorial board for Neurology Reviews, and is a contributing author to MedLink Neurology. K. Selzler and S. Aurora are full-time employees of Eli Lilly and Company.

Table 3 Treatment-emergent AEs that occurred in ≥2% of galcanezumab-treated patients treated with either dose of galcanezumab and greater than placebo

<table>
<thead>
<tr>
<th>AE</th>
<th>Placebo (n = 558), n (%)</th>
<th>Galcanezumab, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>120 mg (n = 273)</td>
<td>240 mg (n = 282)</td>
</tr>
<tr>
<td>Patients with ≥1 events</td>
<td>279 (50)</td>
<td>159 (58)*</td>
</tr>
<tr>
<td>Injection-site pain</td>
<td>24 (4)</td>
<td>17 (6)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>26 (5)</td>
<td>17 (6)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>13 (2)</td>
<td>9 (3)</td>
</tr>
<tr>
<td>Injection-site reaction</td>
<td>10 (2)</td>
<td>8 (3)</td>
</tr>
<tr>
<td>Injection-site erythema</td>
<td>5 (1)</td>
<td>4 (1)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>10 (2)</td>
<td>6 (2)</td>
</tr>
<tr>
<td>Back pain</td>
<td>14 (3)</td>
<td>9 (3)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>7 (1)</td>
<td>6 (2)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>9 (2)</td>
<td>6 (2)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>9 (2)</td>
<td>3 (1)</td>
</tr>
<tr>
<td>Injection-site pruritus</td>
<td>1 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Migraine</td>
<td>5 (1)</td>
<td>5 (2)</td>
</tr>
<tr>
<td>Influenza-like illness</td>
<td>3 (1)</td>
<td>5 (2)</td>
</tr>
<tr>
<td>Neck pain</td>
<td>8 (1)</td>
<td>7 (3)</td>
</tr>
<tr>
<td>Oropharyngeal pain</td>
<td>3 (1)</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>5 (1)</td>
<td>4 (1)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>5 (1)</td>
<td>1 (0)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>2 (0)</td>
<td>5 (2)*</td>
</tr>
</tbody>
</table>

Abbreviation: AE = adverse event.
* p < 0.05 vs placebo.
* p < 0.01 vs placebo.
* p < 0.001 vs placebo.
* p < 0.05 vs galcanezumab 120 mg.
and minor shareholders of Eli Lilly and Company. Go to Neurology.org/N for full disclosures.

**Publication history**

Received by *Neurology* February 28, 2018. Accepted in final form August 9, 2018.

**References**


Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
Holland C. Detke, Peter J. Goadsby, Shufang Wang, et al.
Neurology 2018;91;e2211-e2221 Published Online before print November 16, 2018
DOI 10.1212/WNL.0000000000006640

This information is current as of November 16, 2018

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/91/24/e2211.full

References
This article cites 32 articles, 4 of which you can access for free at:
http://n.neurology.org/content/91/24/e2211.full#ref-list-1

Citations
This article has been cited by 2 HighWire-hosted articles:
http://n.neurology.org/content/91/24/e2211.full##otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Class I
http://n.neurology.org/cgi/collection/class_1
Clinical trials Randomized controlled (CONSORT agreement)
http://n.neurology.org/cgi/collection/clinical_trials_randomized_controlled_consort_agreement
Migraine
http://n.neurology.org/cgi/collection/migraine
Patient safety
http://n.neurology.org/cgi/collection/patient__safety
Quality of life
http://n.neurology.org/cgi/collection/quality_of_life

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise